- Home
- HHS vs CALC Comparison
HHS vs CALC Comparison
Compare HHS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- CALC
- Stock Information
- Founded
- HHS 1923
- CALC 2011
- Country
- HHS United States
- CALC United States
- Employees
- HHS N/A
- CALC N/A
- Industry
- HHS Advertising
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- CALC Health Care
- Exchange
- HHS Nasdaq
- CALC Nasdaq
- Market Cap
- HHS 55.0M
- CALC 44.7M
- IPO Year
- HHS N/A
- CALC N/A
- Fundamental
- Price
- HHS $7.19
- CALC $4.38
- Analyst Decision
- HHS
- CALC Strong Buy
- Analyst Count
- HHS 0
- CALC 4
- Target Price
- HHS N/A
- CALC $20.50
- AVG Volume (30 Days)
- HHS 12.6K
- CALC 41.2K
- Earning Date
- HHS 11-07-2024
- CALC 11-07-2024
- Dividend Yield
- HHS N/A
- CALC N/A
- EPS Growth
- HHS N/A
- CALC N/A
- EPS
- HHS N/A
- CALC N/A
- Revenue
- HHS $187,093,000.00
- CALC N/A
- Revenue This Year
- HHS N/A
- CALC N/A
- Revenue Next Year
- HHS $4.05
- CALC N/A
- P/E Ratio
- HHS N/A
- CALC N/A
- Revenue Growth
- HHS N/A
- CALC N/A
- 52 Week Low
- HHS $5.39
- CALC $1.75
- 52 Week High
- HHS $8.87
- CALC $8.38
- Technical
- Relative Strength Index (RSI)
- HHS 45.85
- CALC 49.58
- Support Level
- HHS $7.09
- CALC $3.98
- Resistance Level
- HHS $7.68
- CALC $4.58
- Average True Range (ATR)
- HHS 0.19
- CALC 0.40
- MACD
- HHS -0.00
- CALC -0.01
- Stochastic Oscillator
- HHS 53.97
- CALC 49.59
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.